Bemcentinib – A selective AXL inhibitor currently in Phase II
Learn MoreNEXT EVENT
BERGENBIO ASA: Invitation to FIRST quarter 2021 results
Date: 19th May 2021 Time: 9:00 am
Scientific Presentations
Virtual Immunology 2021, Dana Bohan et al.
10 May 2021
Phosphatidylserine Receptors Enhancement of SARS-CoV-2 Entry: AXL as a Therapeutic Target for COVID-19
Pipeline of first-in-class AXL inhibitors for the treatment of aggressive diseases.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.
BerGenBio’s lead candidate, bemcentinib, is a once-a-day, oral, highly selective and potent inhibitor of AXL kinase, which has demonstrated a key role in cancer treatment by preventing immune evasion, drug resistance and metastasis in a variety of cancer trials.
Additionally, bemcentinib has been reported to exhibit potent anti-viral activity in preclinical models of infection by enveloped viruses, including Ebola and Zika. Recent data have expanded this to SARS-CoV-2 where findings suggest that bemcentinib stops the virus entering the host cells and neutralising its anti-viral defence mechanisms. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).
Explore BerGenBio’s pipelineLatest News
BERGENBIO TO PRESENT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Bergen, Norway, 28 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has
Read moreBERGENBIO PRE-CLINICAL COVID-19 DATA TO BE PRESENTED AT VIRTUAL IMMUNOLOGY 2021
Bergen, Norway, 26 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a poster presentation
Read moreBERGENBIO ANNOUNCES UPDATE FROM INVESTIGATIONAL PHASE II TRIALS ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
· Day 29 follow-up of last patient enrolled has now occurred in BGBC020 and ACCORD2_002· Data receipt is ongoing and evaluation of efficacy data is underway· Exploratory analyses are
Read moreBERGENBIO ANNOUNCES STOPPED RECRUITMENT TO THE BEMCENTINIB ARM IN UK ACCORD COVID PLATFORM TRIAL
Bergen, Norway, 30 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that recruitment to the bemcentinib arm of
Read more
